Trial record 19 of 231 for:    "Herpes Zoster" [DISEASE]

Safety and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine 1437173A in Healthy Ethnic Japanese Adults

This study has been completed.
Sponsor:
Information provided by:
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT01086449
First received: March 4, 2010
Last updated: December 8, 2011
Last verified: December 2011
  Purpose

The purpose of this study is to evaluate the safety, reactogenicity and immunogenicity of GSK Biologicals' candidate Herpes Zoster (HZ) vaccine in healthy ethnic Japanese adults.


Condition Intervention Phase
Herpes Zoster
Biological: Herpes Zoster Vaccine GSK 1437173A
Phase 1

Study Type: Interventional
Study Design: Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: Safety and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine 1437173A in Healthy Ethnic Japanese Adults

Resource links provided by NLM:


Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Solicited local and general symptoms [ Time Frame: Day 0-6 after each vaccination ] [ Designated as safety issue: No ]
  • Unsolicited adverse events [ Time Frame: Day 0 -29 ] [ Designated as safety issue: No ]
  • Serious adverse events [ Time Frame: From dose 1 up to the end of the study ] [ Designated as safety issue: No ]
  • Occurrence of pre-defined adverse events [ Time Frame: From dose 1 up to study end ] [ Designated as safety issue: No ]
  • Haematological and biochemical parameters [ Time Frame: Months 0, 1 and 3 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Antigen and virus-specific antibody concentrations at protocol-defined time points [ Time Frame: Months 0, 1 and 3 ] [ Designated as safety issue: No ]

Enrollment: 20
Study Start Date: March 2010
Study Completion Date: June 2010
Primary Completion Date: June 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Group A Biological: Herpes Zoster Vaccine GSK 1437173A
Investigational vaccine (GSK 1437173A) administered intramuscularly.

  Eligibility

Ages Eligible for Study:   18 Years to 69 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Subjects who the investigator believes that they can and will comply with the requirements of the protocol (e.g. completion of the diary cards, return for follow-up visits).
  • A male or female between, and including, 18 and 30 years of age at the time of the first vaccination for inclusion in the young adults cohort or aged between, and including, 50 and 69 years of age at the time of the first vaccination for inclusion in the older adults cohort.
  • Written informed consent obtained from the subject.
  • Healthy subjects as established by medical history and clinical examination before entering into the study.
  • Japanese ethnic origin (defined as having been born in Japan with four ethnic Japanese grandparents and able to speak Japanese).
  • Female subjects of non-childbearing potential may be enrolled in the study.

    - Non-childbearing potential is defined as pre-menarche, current tubal ligation, hysterectomy, ovariectomy or post-menopause.

  • Female subjects of childbearing potential may be enrolled in the study, if the subject:

    • has practiced adequate contraception for 30 days prior to vaccination, and
    • has a negative pregnancy test on the day of vaccination, and
    • has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series.
  • Male subjects may be enrolled in the study, if the subject:

    • has agreed to practice adequate contraception (until 2 months after completion of the vaccination series).

Exclusion Criteria:

  • Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine within 30 days preceding the first dose of study vaccine/product, or planned use during the study period.
  • Chronic administration (defined as more than 14 days in total) of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine/product dose. For corticosteroids, this will mean prednisone >= 0.5 mg/kg/day, or equivalent. Inhaled and topical steroids are allowed.
  • Concurrent or planned participation in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).
  • Immunosuppression resulting from haematopoietic stem cell transplantation, AIDS or symptomatic HIV infection.
  • Previous vaccination against HZ (either a registered product or an investigational product through participation in a HZ vaccine study).
  • History of HZ.
  • History of any allergic disease or reaction likely to be exacerbated by any component of the vaccine.
  • Receipt of immunoglobulins and/or any blood products within the three months preceding the first dose of study vaccine or planned administration during the study period.
  • Receipt of any other immunisations within one month before the first study vaccination (2 weeks in the case of inactivated influenza vaccines or other non-replicating immunisation products [e.g., tetanus and reduced dose diphtheria toxoid (dT) vaccine, pneumococcal vaccine, hepatitis A vaccine, hepatitis B vaccine]), or scheduled within 30 days after study vaccination.
  • Acute disease and/or fever at the time of enrolment.
  • Fever is defined as temperature >= 37.5°C (99.5°F) on axillary setting;
  • Subjects with a minor illness (such as mild diarrhoea, mild upper respiratory infection) without fever may, be enrolled at the discretion of the investigator.
  • Pregnant or lactating female.
  • Female planning to become pregnant or planning to discontinue contraceptive precautions (if of child bearing potential).
  • Male planning to father a child or planning to discontinue contraceptive precautions.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01086449

Locations
Australia, New South Wales
GSK Investigational Site
Randwick, New South Wales, Australia, 2031
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

No publications provided by GlaxoSmithKline

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Cheri Hudson; Clinical Disclosure Advisor, GSK Clinical Disclosure
ClinicalTrials.gov Identifier: NCT01086449     History of Changes
Other Study ID Numbers: 113819
Study First Received: March 4, 2010
Last Updated: December 8, 2011
Health Authority: Australia: Department of Health and Ageing Therapeutic Goods Administration

Keywords provided by GlaxoSmithKline:
safety
Japanese
Herpes Zoster
immunogenicity
Herpes Zoster in healthy ethnic Japanese adults
Vaccine

Additional relevant MeSH terms:
Herpes Zoster
Herpesviridae Infections
DNA Virus Infections
Virus Diseases

ClinicalTrials.gov processed this record on July 24, 2014